In vitro potency of various polymyxin B components.
作者信息
Tam Vincent H, Cao Henry, Ledesma Kimberly R, Hu Ming
出版信息
Antimicrob Agents Chemother. 2011 Sep;55(9):4490-1. doi: 10.1128/AAC.00119-11. Epub 2011 Jun 27.
Abstract
摘要
相似文献
1
In vitro potency of various polymyxin B components.多种多粘菌素B组分的体外效价
Antimicrob Agents Chemother. 2011 Sep;55(9):4490-1. doi: 10.1128/AAC.00119-11. Epub 2011 Jun 27.
2
Microbiological Assessment of Polymyxin B Components Tested Alone and in Combination.单独及联合测试的多粘菌素B组分的微生物学评估
Antimicrob Agents Chemother. 2015 Dec;59(12):7823-5. doi: 10.1128/AAC.01021-15. Epub 2015 Sep 21.
3
Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.多粘菌素B的矛盾效应：高药物暴露会增强鲍曼不动杆菌的耐药性
Antimicrob Agents Chemother. 2016 Jun 20;60(7):3913-20. doi: 10.1128/AAC.02831-15. Print 2016 Jul.
4
In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii.美罗培南联合多黏菌素B和加替沙星对铜绿假单胞菌和鲍曼不动杆菌抗菌活性的体外评价
J Chemother. 2008 Apr;20(2):180-5. doi: 10.1179/joc.2008.20.2.180.
5
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.多黏菌素 B、利福平与多利培南对多重耐药鲍曼不动杆菌、铜绿假单胞菌、肺炎克雷伯菌和大肠埃希菌体外联合杀菌活性研究
Antimicrob Agents Chemother. 2010 Jun;54(6):2732-4. doi: 10.1128/AAC.01768-09. Epub 2010 Apr 5.
6
From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.从乳腺癌到抗菌：利用多粘菌素B与选择性雌激素受体调节剂的新型组合对抗极具耐药性的革兰氏阴性“超级细菌”
Microb Drug Resist. 2017 Jul;23(5):640-650. doi: 10.1089/mdr.2016.0196. Epub 2016 Dec 9.
7
Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.比较多黏菌素 B 和黏菌素对多重耐药革兰氏阴性菌的抗菌活性。
Infect Dis (Lond). 2019 Sep;51(9):676-682. doi: 10.1080/23744235.2019.1640386. Epub 2019 Jul 12.
8
Synergistic combinations of polymyxins.多粘菌素的协同组合。
Int J Antimicrob Agents. 2016 Dec;48(6):607-613. doi: 10.1016/j.ijantimicag.2016.09.014. Epub 2016 Oct 24.
9
In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria.环吡酮作为多粘菌素B抗革兰氏阴性菌佐剂的体外评价
J Antibiot (Tokyo). 2015 Jun;68(6):395-8. doi: 10.1038/ja.2014.164. Epub 2015 Jan 14.
10
Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates.多黏菌素对鲍曼不动杆菌、铜绿假单胞菌和肺炎克雷伯菌临床分离株的突变预防浓度。
J Antimicrob Chemother. 2014 Jan;69(1):275-7. doi: 10.1093/jac/dkt315. Epub 2013 Aug 29.
引用本文的文献
1
Pharmacodynamic Profile of EVER206, a Novel Polymyxin Antimicrobial, against Gram-Negative Bacteria in the Murine Thigh Infection Model.新型多黏菌素类抗菌药物 EVER206 的药效学特征：在小鼠大腿感染模型中对革兰氏阴性菌的作用。
Antimicrob Agents Chemother. 2023 May 17;67(5):e0173822. doi: 10.1128/aac.01738-22. Epub 2023 Apr 6.
2
Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice.通过群体药代动力学模拟多粘菌素 B 的各个成分，为免疫功能正常的小鼠的血流和肺部感染模型设计人性化的剂量方案。
Antimicrob Agents Chemother. 2023 May 17;67(5):e0019723. doi: 10.1128/aac.00197-23. Epub 2023 Apr 6.
3
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids.合成及评价带有还原性不稳定双硫键连接脂质的多粘菌素。
J Med Chem. 2022 Dec 8;65(23):15878-15892. doi: 10.1021/acs.jmedchem.2c01528. Epub 2022 Nov 18.
4
Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections.多黏菌素B在肥胖患者中治疗耐革兰阴性菌感染的群体药代动力学
Front Pharmacol. 2021 Nov 22;12:754844. doi: 10.3389/fphar.2021.754844. eCollection 2021.
5
Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.比较有或无肾功能不全的中国患者中多黏菌素 B 的群体药代动力学和急性肾损伤。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.01900-20.
6
Population Pharmacokinetics and Limited Sampling Strategy for Therapeutic Drug Monitoring of Polymyxin B in Chinese Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.中国多重耐药革兰阴性菌感染患者多黏菌素B治疗药物监测的群体药代动力学与有限采样策略
Front Pharmacol. 2020 Jun 5;11:829. doi: 10.3389/fphar.2020.00829. eCollection 2020.
7
Direct modifications of the cyclic peptide Polymyxin B leading to analogues with enhanced in vitro antibacterial activity.直接修饰环肽多粘菌素 B 得到具有增强体外抗菌活性的类似物。
Bioorg Med Chem Lett. 2020 Jun 1;30(11):127163. doi: 10.1016/j.bmcl.2020.127163. Epub 2020 Mar 30.
8
Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.多黏菌素类药物的药敏试验：挑战、问题和建议。
J Clin Microbiol. 2019 Mar 28;57(4). doi: 10.1128/JCM.01390-18. Print 2019 Apr.
9
A Rapid and Semi-Quantitative Gold Nanoparticles Based Strip Sensor for Polymyxin B Sulfate Residues.一种基于金纳米颗粒的快速半定量纸条传感器，用于检测硫酸多粘菌素B残留。
Nanomaterials (Basel). 2018 Mar 5;8(3):144. doi: 10.3390/nano8030144.
10
Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.多粘菌素B用于耐多药/广泛耐药革兰氏阴性菌感染的复苏：当前证据概述
Crit Care Res Pract. 2017;2017:3635609. doi: 10.1155/2017/3635609. Epub 2017 Jul 6.
本文引用的文献
1
Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa.铜绿假单胞菌血流感染的多重耐药株的流行率、耐药机制和药敏情况。
Antimicrob Agents Chemother. 2010 Mar;54(3):1160-4. doi: 10.1128/AAC.01446-09. Epub 2010 Jan 19.
2
Variability of polymyxin B major components in commercial formulations.市售制剂中多粘菌素B主要成分的变异性。
Int J Antimicrob Agents. 2010 Mar;35(3):308-10. doi: 10.1016/j.ijantimicag.2009.11.005. Epub 2009 Dec 31.
3
Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae.外膜孔蛋白K36对产KPC肺炎克雷伯菌碳青霉烯类药物敏感性的影响
J Med Microbiol. 2009 Oct;58(Pt 10):1303-1308. doi: 10.1099/jmm.0.012575-0. Epub 2009 Jun 25.
4
Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection.在耐碳青霉烯类肺炎克雷伯菌感染治疗期间对多粘菌素B的敏感性降低。
J Clin Microbiol. 2009 May;47(5):1611-2. doi: 10.1128/JCM.02466-08. Epub 2009 Mar 4.
5
Comment on: Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma.评论：人血浆中多粘菌素B的反相高效液相色谱测定法的开发与验证
J Antimicrob Chemother. 2009 Mar;63(3):627-8; author reply 628-9. doi: 10.1093/jac/dkn483. Epub 2008 Nov 19.
6
Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms.多粘菌素B：针对多重耐药革兰氏阴性菌的新策略。
Expert Opin Investig Drugs. 2008 May;17(5):661-8. doi: 10.1517/13543784.17.5.661.
7
Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.产碳青霉烯酶OXA-40的耐碳青霉烯鲍曼不动杆菌分离株的多城市暴发
Antimicrob Agents Chemother. 2006 Sep;50(9):2941-5. doi: 10.1128/AAC.00116-06.
8
Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B.全市范围内出现对多粘菌素B敏感性降低的铜绿假单胞菌菌株。
J Antimicrob Chemother. 2005 Jun;55(6):954-7. doi: 10.1093/jac/dki153. Epub 2005 May 9.
9
Isolation and structural characterization of polymyxin B components.多粘菌素B组分的分离与结构表征
J Chromatogr A. 2001 Apr 6;912(2):369-73. doi: 10.1016/s0021-9673(01)00585-4.
Zotero 插件